LIB Therapeutics
Privately held: no public share price
Assets
(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
Lerodalcibep(Lerochol) | Phase 3 | PCSK9Protein / enzyme therapeutic | Atherosclerotic Cardiovascular Disease |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
26 June 2026Filing acceptedLerodalcibepNMPA accepts the LEROCHOL (lerodalcibep) BLA for hypercholesterolemia
CN, NMPA · Everest Medicines · Source ↗
Financial reports
No financial reports recorded.